You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyproheptadine
Accession NumberDB00434  (APRD00033)
TypeSmall Molecule
GroupsApproved
DescriptionA serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [PubChem]
Structure
Thumb
Synonyms
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
Axoprol
Ciproheptadina
Cyproheptadin
Cyproheptadine
Cyproheptadinum
Dihexazin
Glutodina
External Identifiers
  • Fl 5967
  • HSp 1229
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyproheptadineSyrup2 mg/5mLOralPharmaceutical Associates, Inc.2013-07-29Not applicableUs
CyproheptadineSyrup2 mg/5mLOralPharmaceutical Associates, Inc.2013-07-29Not applicableUs
Cyproheptadine HydrochlorideSyrup2 mg/5mLOralCarilion Materials Management2006-07-10Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralREMEDYREPACK INC.2011-09-222016-11-10Us
Cyproheptadine HydrochlorideTablet4 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralTeva Pharmaceuticals USA Inc2009-01-23Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralREMEDYREPACK INC.2012-08-162016-10-13Us
Cyproheptadine HydrochlorideSyrup2 mg/5mLOralActavis Mid Atlantic LLC2009-07-31Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1Oralbryant ranch prepack2009-01-23Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralIngenus Pharmaceuticals Nj, Llc2015-09-23Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralREMEDYREPACK INC.2011-09-202016-11-08Us
Cyproheptadine HydrochlorideTablet4 mg/1OralPhysicians Total Care, Inc.2003-05-21Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralREMEDYREPACK INC.2013-12-312016-04-05Us
Cyproheptadine HydrochlorideTablet4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-08Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralCore Pharma, Llc2015-07-29Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralCarilion Materials Management2010-06-15Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralIngenus Pharmaceuticals Llc2015-09-23Not applicableUs
Cyproheptadine HydrochlorideSyrup2 mg/5mLOralPhysicians Total Care, Inc.2009-07-31Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Cyproheptadine HydrochlorideSyrup2 mg/5mLOralRising Pharmaceuticals, Inc.2006-07-10Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralAv Kare, Inc.2010-06-15Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralREMEDYREPACK INC.2016-08-16Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralBreckenridge Pharmaceutical, Inc.2013-10-21Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralCardinal Health2010-06-15Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralC.O. Truxton, Inc.2010-06-15Not applicableUs
Cyproheptadine HydrochlorideTablet4 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyproheptadine 4mg TabletsTablet4 mgOralJamp Pharma Corporation2010-05-03Not applicableCanada
Euro-cyproheptadine 2mg/5mlSyrup2 mgOralSandoz Canada Incorporated2003-05-27Not applicableCanada
Euro-cyproheptadine 4mg/tabletTablet4 mgOralSandoz Canada Incorporated2006-06-05Not applicableCanada
Jamp Cyproheptadine SyrupSyrup0.4 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Periactin Syr 2mg/5mlSyrup2 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1961-12-312002-07-29Canada
Periactin Tab 4mgTablet4 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1961-12-312002-07-29Canada
PMS-cyproheptadine HCl Tab 4mgTablet4 mgOralPharmascience Inc1996-10-16Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
ApeplusRadicura
ApitupUniversal
BioheptBiofarm
CiplactinCipla
CipractineTeriak
CiproheptadinaArena
CiprovitNot Available
CiptadineIBN
CyheptineGreater Pharma
CyllerminCCPC
PeriactinMerck
PeriactineTeofarma
PeriatinApex
ReactinOrion
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cyproheptadine Hydrochloride
969-33-5
Thumb
  • InChI Key: ZPMVNZLARAEGHB-UHFFFAOYSA-N
  • Monoisotopic Mass: 323.144077416
  • Average Mass: 323.859
DBSALT000625
Categories
UNII2YHB6175DO
CAS number129-03-3
WeightAverage: 287.3981
Monoisotopic: 287.167399677
Chemical FormulaC21H21N
InChI KeyJJCFRYNCJDLXIK-UHFFFAOYSA-N
InChI
InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
IUPAC Name
1-methyl-4-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine
SMILES
CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12
Pharmacology
IndicationFor treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine.
Structured Indications
PharmacodynamicsCyproheptadine is a piperidine antihistamine. Unlike other antihistamines, this drug also antagonizes serotonin receptors. This action makes Cyproheptadine useful in conditions such as vascular headache and anorexia. Cyproheptadine does not prevent the release of histamine but rather competes with free histamine for binding at HA-receptor sites. Cyproheptadine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. Most antihistamines possess significant anticholinergic properties, but Cyproheptadine exerts only weak anticholinergic actions. Blockade of central muscarinic receptors appears to account for Cyproheptadine's antiemetic effects, although the exact mechanism is unknown. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite. Cyproheptadine also has been used to counter vascular headaches, which many believe are caused by changes in serotonin activity, however it is unclear how Cyproheptadine exerts a beneficial effect on this condition.
Mechanism of actionCyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinyes
antagonist
HumanP28335 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Related Articles
AbsorptionWell absorbed after oral administration.
Volume of distributionNot Available
Protein binding96 to 99%
Metabolism

Hepatic (cytochrome P-450 system) and some renal.

Route of eliminationAfter a single 4 mg oral dose of14C-labelled cyproheptadine HCl in normal subjects, given as tablets 2% to 20% of the radioactivity was excreted in the stools. At least 40% of the administered radioactivity was excreted in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cyproheptadine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyproheptadine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Cyproheptadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cyproheptadine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cyproheptadine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the anticholinergic activities of Cyproheptadine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Cyproheptadine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyproheptadine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Cyproheptadine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyproheptadine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cyproheptadine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyproheptadine.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cyproheptadine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyproheptadine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyproheptadine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyproheptadine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyproheptadine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Cyproheptadine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Cyproheptadine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyproheptadine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Cyproheptadine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyproheptadine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Cyproheptadine.Vet Approved
AzelastineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Cyproheptadine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Cyproheptadine.Illicit
BenmoxinBenmoxin may increase the anticholinergic activities of Cyproheptadine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Cyproheptadine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Cyproheptadine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cyproheptadine.Approved
Benzylpenicilloyl PolylysineCyproheptadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cyproheptadine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyproheptadine.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Cyproheptadine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyproheptadine.Approved, Investigational
BuprenorphineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyproheptadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyproheptadine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Cyproheptadine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Cyproheptadine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Cyproheptadine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Cyproheptadine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyproheptadine.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyproheptadine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cyproheptadine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyproheptadine.Approved
CaroxazoneCaroxazone may increase the anticholinergic activities of Cyproheptadine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyproheptadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyproheptadine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyproheptadine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Cyproheptadine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyproheptadine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Cyproheptadine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyproheptadine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyproheptadine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyproheptadine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyproheptadine.Approved, Vet Approved
CitalopramThe therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cyproheptadine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Cyproheptadine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Cyproheptadine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyproheptadine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyproheptadine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyproheptadine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyproheptadine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyproheptadine.Approved
DapoxetineThe therapeutic efficacy of Dapoxetine can be decreased when used in combination with Cyproheptadine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Cyproheptadine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyproheptadine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe therapeutic efficacy of Desvenlafaxine can be decreased when used in combination with Cyproheptadine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Cyproheptadine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyproheptadine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Cyproheptadine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyproheptadine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyproheptadine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cyproheptadine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyproheptadine.Approved, Illicit, Vet Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Cyproheptadine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyproheptadine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyproheptadine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyproheptadine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyproheptadine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyproheptadine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Cyproheptadine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyproheptadine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Cyproheptadine.Experimental, Illicit
DuloxetineThe therapeutic efficacy of Duloxetine can be decreased when used in combination with Cyproheptadine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Cyproheptadine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Cyproheptadine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cyproheptadine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Entacapone.Approved, Investigational
EscitalopramThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Cyproheptadine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyproheptadine.Approved
EthanolCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyproheptadine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyproheptadine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cyproheptadine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyproheptadine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Cyproheptadine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Cyproheptadine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Cyproheptadine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyproheptadine.Approved
EtoperidoneThe therapeutic efficacy of Etoperidone can be decreased when used in combination with Cyproheptadine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyproheptadine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyproheptadine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyproheptadine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyproheptadine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cyproheptadine.Approved, Illicit
FluoxetineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyproheptadine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyproheptadine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyproheptadine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyproheptadine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fluticasone Propionate.Approved
FluvoxamineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Cyproheptadine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cyproheptadine.Approved, Illicit
FurazolidoneFurazolidone may increase the anticholinergic activities of Cyproheptadine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyproheptadine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Cyproheptadine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Cyproheptadine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cyproheptadine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyproheptadine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Cyproheptadine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cyproheptadine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyproheptadine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyproheptadine.Approved, Investigational
HydracarbazineHydracarbazine may increase the anticholinergic activities of Cyproheptadine.Approved
HydrocodoneCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyproheptadine.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Cyproheptadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Imipramine.Approved
IndalpineThe therapeutic efficacy of Indalpine can be decreased when used in combination with Cyproheptadine.Investigational, Withdrawn
IproclozideIproclozide may increase the anticholinergic activities of Cyproheptadine.Withdrawn
IproniazidIproniazid may increase the anticholinergic activities of Cyproheptadine.Withdrawn
IsocarboxazidIsocarboxazid may increase the anticholinergic activities of Cyproheptadine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyproheptadine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyproheptadine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyproheptadine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyproheptadine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Cyproheptadine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyproheptadine.Approved
LevomilnacipranThe therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Cyproheptadine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyproheptadine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cyproheptadine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Cyproheptadine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Cyproheptadine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cyproheptadine.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyproheptadine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyproheptadine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Cyproheptadine.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the anticholinergic activities of Cyproheptadine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Cyproheptadine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Cyproheptadine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Cyproheptadine.Approved
MephedroneMephedrone may decrease the sedative activities of Cyproheptadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Cyproheptadine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyproheptadine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyproheptadine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyproheptadine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cyproheptadine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Cyproheptadine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyproheptadine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cyproheptadine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyproheptadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyproheptadine.Approved
MethotrimeprazineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyproheptadine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methsuximide.Approved
Methylene blueMethylene blue may increase the anticholinergic activities of Cyproheptadine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyproheptadine.Approved
MetyrosineCyproheptadine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine.Approved, Illicit
MilnacipranThe therapeutic efficacy of Milnacipran can be decreased when used in combination with Cyproheptadine.Approved
MinaprineMinaprine may increase the anticholinergic activities of Cyproheptadine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved, Investigational
MirtazapineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Cyproheptadine.Experimental, Illicit
MoclobemideMoclobemide may increase the anticholinergic activities of Cyproheptadine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Cyproheptadine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyproheptadine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyproheptadine.Approved
NefazodoneThe therapeutic efficacy of Nefazodone can be decreased when used in combination with Cyproheptadine.Approved, Withdrawn
NialamideNialamide may increase the anticholinergic activities of Cyproheptadine.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyproheptadine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Cyproheptadine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cyproheptadine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the anticholinergic activities of Cyproheptadine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyproheptadine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cyproheptadine.Approved, Illicit
OrphenadrineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyproheptadine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyproheptadine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyproheptadine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyproheptadine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyproheptadine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyproheptadine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyproheptadine.Approved
ParaldehydeCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the anticholinergic activities of Cyproheptadine.Approved
ParoxetineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyproheptadine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Cyproheptadine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyproheptadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyproheptadine.Approved
PhenelzinePhenelzine may increase the anticholinergic activities of Cyproheptadine.Approved
PheniprazinePheniprazine may increase the anticholinergic activities of Cyproheptadine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyproheptadine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Cyproheptadine.Approved
PhenoxypropazinePhenoxypropazine may increase the anticholinergic activities of Cyproheptadine.Withdrawn
PhenterminePhentermine may decrease the sedative activities of Cyproheptadine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cyproheptadine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyproheptadine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyproheptadine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the anticholinergic activities of Cyproheptadine.Approved
PivhydrazinePivhydrazine may increase the anticholinergic activities of Cyproheptadine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pomalidomide.Approved
PramipexoleCyproheptadine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Cyproheptadine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyproheptadine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyproheptadine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Cyproheptadine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cyproheptadine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyproheptadine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyproheptadine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyproheptadine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyproheptadine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Cyproheptadine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Cyproheptadine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Cyproheptadine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyproheptadine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyproheptadine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ramelteon.Approved, Investigational
RasagilineRasagiline may increase the anticholinergic activities of Cyproheptadine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyproheptadine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyproheptadine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyproheptadine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyproheptadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Cyproheptadine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Cyproheptadine.Vet Approved
RopiniroleCyproheptadine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyproheptadine.Approved
RotigotineCyproheptadine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyproheptadine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyproheptadine.Experimental
SafrazineSafrazine may increase the anticholinergic activities of Cyproheptadine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyproheptadine.Approved, Vet Approved
SelegilineSelegiline may increase the anticholinergic activities of Cyproheptadine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Cyproheptadine.Approved, Withdrawn
SertralineThe therapeutic efficacy of Sertraline can be decreased when used in combination with Cyproheptadine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyproheptadine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyproheptadine.Approved
SuvorexantCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyproheptadine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Cyproheptadine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cyproheptadine.Investigational
ThalidomideCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyproheptadine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyproheptadine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyproheptadine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyproheptadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Cyproheptadine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyproheptadine.Approved, Withdrawn
ToloxatoneToloxatone may increase the anticholinergic activities of Cyproheptadine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyproheptadine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyproheptadine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Cyproheptadine.Experimental
TranylcypromineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyproheptadine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyproheptadine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyproheptadine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyproheptadine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyproheptadine.Approved
Uc1010The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cyproheptadine.Approved, Investigational
VenlafaxineThe therapeutic efficacy of Venlafaxine can be decreased when used in combination with Cyproheptadine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyproheptadine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Cyproheptadine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyproheptadine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ziconotide.Approved
ZimelidineThe therapeutic efficacy of Zimelidine can be decreased when used in combination with Cyproheptadine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyproheptadine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Cyproheptadine.Vet Approved
ZolpidemCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Cyproheptadine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Cyproheptadine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyproheptadine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
References
Synthesis Reference

Engelhardt, E.L.; U S . Patent 3,014,911; December 26, 1961; assigned to Merck & Co., Inc.

General References
  1. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
External Links
ATC CodesR06AX02
AHFS Codes
  • 04:04.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.986
Caco-2 permeable+0.8038
P-glycoprotein substrateSubstrate0.8598
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.5315
Renal organic cation transporterInhibitor0.8303
CYP450 2C9 substrateNon-substrate0.8127
CYP450 2D6 substrateNon-substrate0.6719
CYP450 3A4 substrateSubstrate0.6092
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9082
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5433
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9511
BiodegradationNot ready biodegradable0.8349
Rat acute toxicity2.9576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5429
hERG inhibition (predictor II)Inhibitor0.7423
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
SyrupOral2 mg/5mL
TabletOral4 mg
TabletOral4 mg/1
SyrupOral0.4 mg
SyrupOral2 mg
Prices
Unit descriptionCostUnit
Cyproheptadine hcl powder7.34USD g
Cyproheptadine HCl 4 mg tablet0.47USD tablet
Cyproheptadine 4 mg tablet0.43USD tablet
Cyproheptadine HCl 2 mg/5ml Syrup0.16USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point112.3-113-3Engelhardt, E.L.; U S . Patent 3,014,911; December 26, 1961; assigned to Merck & Co., Inc.
water solubilitySolubleNot Available
logP4.69SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP5.02ALOGPS
logP4.38ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity105.17 m3·mol-1ChemAxon
Polarizability34.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00kr-2290000000-a17c27a9f171b058f2c3View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Rashid M, Nakazawa M, Nagatomo T: Effects of sarpogrelate, a novel 5-HT2 antagonist, on 5-HT-induced endothelium-dependent relaxations in porcine coronary artery. Jpn J Pharmacol. 2002 Aug;89(4):405-12. [PubMed:12233819 ]
  2. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911 ]
  3. Callaway CW, Rempel N, Peng RY, Geyer MA: Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology. 1992 Sep;7(2):113-27. [PubMed:1358088 ]
  4. Hoenicke EM, Vanecek SA, Woods JH: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther. 1992 Oct;263(1):276-84. [PubMed:1403790 ]
  5. Calka O, Metin A, Dulger H, Erkoc R: Effect of cyproheptadine on serum leptin levels. Adv Ther. 2005 Sep-Oct;22(5):424-8. [PubMed:16418149 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22. [PubMed:2625138 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22. [PubMed:2625138 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22. [PubMed:2625138 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. [PubMed:9616184 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11